➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
Johnson and Johnson
McKesson
Medtronic
Merck
Dow

Last Updated: August 6, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Otamixaban

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the drug development status for Otamixaban?

Otamixaban is an investigational drug.

There have been 5 clinical trials for Otamixaban. The most recent clinical trial was a Phase 3 trial, which was initiated on April 1st 2010.

The most common disease conditions in clinical trials are Acute Coronary Syndrome, Myocardial Infarction, and Infarction. The leading clinical trial sponsors are Sanofi and [disabled in preview].

Recent Clinical Trials for Otamixaban
TitleSponsorPhase
Pharmacokinetic, Pharmacodynamic and Tolerability Study of Otamixaban in Patients With Mild and Moderate Hepatic ImpairmentSanofiPhase 1
Effect of Otamixaban Versus Unfractionated Heparin + Eptifibatide in Patients With Unstable Angina/Non ST Elevation Myocardial Infarction Undergoing Early Invasive StrategySanofiPhase 3
Pharmacokinetic, Pharmacodynamic and Tolerability Study of Otamixaban in Patients With Mild, Moderate and Severe Renal ImpairmentSanofiPhase 1

See all Otamixaban clinical trials

Clinical Trial Summary for Otamixaban

Top disease conditions for Otamixaban
Top clinical trial sponsors for Otamixaban

See all Otamixaban clinical trials

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Johnson and Johnson
McKesson
Medtronic
Merck
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.